EC 2.4.2.* (pentosyltransferase) inhibitor - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	*EC 2.4.2. (pentosyltransferase) inhibitor**	go back to main search page
Accession:	CHEBI:76790	browse the term
Definition:	An EC 2.4.* (glycosyltransferase) inhibitor that interferes with the action of any pentosyltransferase (EC 2.4.2.*).
Synonyms:	related_synonym:	EC 2.4.2.* (pentosyltransferase) inhibitors; EC 2.4.2.* inhibitor; EC 2.4.2.* inhibitors; pentosyltransferase inhibitor; pentosyltransferase inhibitors

show annotations for term's descendants Sort by:
Rat (261) Mouse (262) Human (262) Chinchilla (0) Bonobo (0) Dog (3) Squirrel (0) Pig (3) Green Monkey (0) Naked Mole-rat (0) All
Genes (261)

1-methylnicotinamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA]

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

DEK proto-oncogene

decreases chemical synthesis

DEK protein results in decreased chemical synthesis of N(1)-methylnicotinamide

NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808

G

leptin receptor

affects abundance

LEPR affects the abundance of N(1)-methylnicotinamide

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

luteinizing hormone subunit beta

multiple interactions

N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

nicotinamide phosphoribosyltransferase

multiple interactions

N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA]

NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100

G

prostaglandin-endoperoxide synthase 2

increases expression

N(1)-methylnicotinamide results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

resistin

multiple interactions

N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of RETN mRNA]

NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620

G

solute carrier family 22 member 1

increases import

SLC22A1 results in increased import of N(1)-methylnicotinamide

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 22 member 16

multiple interactions

N(1)-methylnicotinamide inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium]

NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019

G

solute carrier family 22 member 2

increases import

SLC22A2 results in increased import of N(1)-methylnicotinamide

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 22 member 3

multiple interactions

N(1)-methylnicotinamide inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]

NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612

3-aminobenzamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions

3-aminobenzamide promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]
3-aminobenzamide promotes the reaction [Alitretinoin promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]]; 3-aminobenzamide promotes the reaction [Alitretinoin results in increased expression of ABCA1 mRNA]; 3-aminobenzamide promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

adiponectin, C1Q and collagen domain containing

increases expression

3-aminobenzamide results in increased expression of ADIPOQ mRNA

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adiponectin receptor 1

increases expression

3-aminobenzamide results in increased expression of ADIPOR1 mRNA

NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241

G

adiponectin receptor 2

increases expression

3-aminobenzamide results in increased expression of ADIPOR2 mRNA

NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355

G

ATM serine/threonine kinase

multiple interactions

3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of ATM protein]

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

bone gamma-carboxyglutamate protein

increases expression

3-aminobenzamide results in increased expression of BGLAP mRNA

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

caspase 3

multiple interactions

3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; 3-aminobenzamide inhibits the reaction [SFRP1 protein promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]
3-aminobenzamide inhibits the reaction [[oxyhyponitrite results in increased abundance of nitroxyl] which results in increased activity of CASP3 protein]

PMID:11744336 PMID:16505238 PMID:30377735

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin D1

decreases expression

3-aminobenzamide results in decreased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

CD36 molecule

increases expression

3-aminobenzamide results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cyclin-dependent kinase inhibitor 1A

increases expression

3-aminobenzamide results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

catenin beta 1

decreases expression

3-aminobenzamide results in decreased expression of CTNNB1 mRNA

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

C-X-C motif chemokine ligand 2

multiple interactions

3-aminobenzamide inhibits the reaction [Bleomycin results in increased secretion of CXCL2 protein]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

E2F transcription factor 1

multiple interactions

3-aminobenzamide promotes the reaction [RB1 protein binds to E2F1 protein]

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

E1A binding protein p300

multiple interactions

3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of EP300 mRNA]

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

ERCC excision repair 1, endonuclease non-catalytic subunit

multiple interactions
decreases expression

3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 protein]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC1 mRNA]
3-aminobenzamide results in decreased expression of ERCC1 mRNA; 3-aminobenzamide results in decreased expression of ERCC1 protein

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

ERCC excision repair 4, endonuclease catalytic subunit

multiple interactions
decreases expression

3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 protein]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC4 mRNA]
3-aminobenzamide results in decreased expression of ERCC4 mRNA; 3-aminobenzamide results in decreased expression of ERCC4 protein

NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369

G

ERCC excision repair 6, chromatin remodeling factor

multiple interactions
affects response to substance

3-aminobenzamide inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]
ERCC6 gene mutant form affects the susceptibility to 3-aminobenzamide

NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587

G

fibronectin 1

multiple interactions
decreases expression

3-aminobenzamide inhibits the reaction [Glucose results in increased expression of FN1 mRNA]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of FN1 mRNA]
3-aminobenzamide results in decreased expression of FN1 protein

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

HRas proto-oncogene, GTPase

multiple interactions

3-aminobenzamide inhibits the reaction [hydroquinone results in increased expression of HRAS protein]

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

inhibitor of DNA binding 2

decreases expression

3-aminobenzamide results in decreased expression of ID2 mRNA

NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400

G

interleukin 1 beta

multiple interactions

3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

insulin 2

multiple interactions

3-aminobenzamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of INS protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases expression

3-aminobenzamide results in decreased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

leptin

increases expression

3-aminobenzamide results in increased expression of LEP mRNA

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lipoprotein lipase

increases expression

3-aminobenzamide results in increased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

MAF bZIP transcription factor A

multiple interactions

3-aminobenzamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]
3-aminobenzamide inhibits the reaction [Glucose results in decreased expression of MAFA mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in decreased expression of MAFA protein]

NCBI chr 7:107,432,292...107,435,084
Ensembl chr 7:107,433,605...107,434,690

G

microRNA 126a

decreases expression
multiple interactions

3-aminobenzamide results in decreased expression of MIR126 mRNA
3-aminobenzamide inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA]; [Decitabine co-treated with 3-aminobenzamide] inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA]

NCBI chr 3:9,415,063...9,415,180
Ensembl chr 3:9,415,063...9,415,180

G

myeloperoxidase

multiple interactions

3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

3-aminobenzamide results in decreased expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

NFKB inhibitor alpha

multiple interactions

3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NFKBIA mRNA]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nuclear receptor subfamily 1, group H, member 3

decreases ADP-ribosylation

3-aminobenzamide results in decreased ADP-ribosylation of NR1H3 protein

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

poly (ADP-ribose) polymerase 1

multiple interactions
decreases activity

3-aminobenzamide inhibits the reaction [Asbestos, Amosite results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Asbestos, Crocidolite results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Benzoyl Peroxide results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Capsaicin results in increased ADP-ribosylation of PARP1 protein modified form]; 3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [hydroquinone results in increased expression of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Lithocholic Acid analog results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [mezerein results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [PARP1 protein results in increased susceptibility to [Potassium Dichromate co-treated with nickel sulfate]]; 3-aminobenzamide inhibits the reaction [Smoke analog results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [sodium arsenite results in decreased expression of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of PARP1 protein]; 3-aminobenzamide promotes the reaction [Capsaicin results in increased cleavage of and results in increased activity of PARP1 protein]; 3-aminobenzamide promotes the reaction [Capsaicin results in increased expression of PARP1 protein]; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [3-aminobenzamide results in decreased activity of PARP1 protein] which results in increased susceptibility to Cisplatin
3-aminobenzamide inhibits the reaction [[sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in increased cleavage of PARP1 protein]; 3-aminobenzamide inhibits the reaction [sodium arsenite results in increased cleavage of PARP1 protein]
3-aminobenzamide inhibits the reaction [PARP1 protein results in increased susceptibility to Acetaminophen]

PMID:2120135 PMID:2126186 PMID:11217149 PMID:15075382 PMID:15601672 More...

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

poly (ADP-ribose) polymerase 2

affects binding

PARP2 protein binds to 3-aminobenzamide

NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338

G

proliferating cell nuclear antigen

increases expression

3-aminobenzamide results in increased expression of PCNA protein

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

pancreatic and duodenal homeobox 1

multiple interactions

3-aminobenzamide inhibits the reaction [Palmitic Acid results in decreased expression of PDX1 protein]

NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064

G

peroxisome proliferator-activated receptor gamma

increases activity
multiple interactions
decreases ADP-ribosylation

3-aminobenzamide results in increased activity of PPARG protein
3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein]
3-aminobenzamide results in decreased ADP-ribosylation of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein kinase, DNA-activated, catalytic subunit

multiple interactions

3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of PRKDC protein]

NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952

G

RB transcriptional corepressor 1

multiple interactions

3-aminobenzamide promotes the reaction [RB1 protein binds to E2F1 protein]; 3-aminobenzamide results in decreased phosphorylation of and results in increased activity of RB1 protein

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

3-aminobenzamide inhibits the reaction [Methylnitrosourea results in decreased expression of RELA protein modified form]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

secreted frizzled-related protein 1

multiple interactions

3-aminobenzamide inhibits the reaction [SFRP1 protein promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]

NCBI chr16:68,575,763...68,614,180
Ensembl chr16:68,575,763...68,614,286

G

secreted phosphoprotein 1

increases expression

3-aminobenzamide results in increased expression of SPP1 mRNA

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

serine/threonine kinase 11

multiple interactions

3-aminobenzamide inhibits the reaction [resveratrol results in increased phosphorylation of STK11 protein]

NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315

G

telomerase reverse transcriptase

multiple interactions

3-aminobenzamide inhibits the reaction [TERT protein mutant form results in decreased susceptibility to temozolomide]

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

tumor protein p53

multiple interactions

3-aminobenzamide inhibits the reaction [Capsaicin results in increased expression of TP53 protein]; 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

8-azaguanine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

microtubule-associated protein tau

decreases expression

Azaguanine results in decreased expression of MAPT protein

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

didanosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

albumin

affects binding

Didanosine binds to ALB protein

PMID:15814459 PMID:16336266

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

homeostatic iron regulator

multiple interactions

HFE gene SNP affects the susceptibility to [Didanosine co-treated with Stavudine]

NCBI chr17:41,413,451...41,421,502
Ensembl chr17:41,413,451...41,421,502

G

interleukin 24

decreases expression

Didanosine results in decreased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

mitochondrially encoded cytochrome c oxidase II

decreases expression
multiple interactions

Didanosine results in decreased expression of COX2 mRNA
tenofovir promotes the reaction [Didanosine results in decreased expression of COX2 mRNA]

NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689

G

solute carrier family 29 member 3

affects transport

SLC29A3 protein affects the transport of Didanosine

NCBI chr20:28,645,265...28,685,388
Ensembl chr20:28,647,391...28,685,388

G

secretory leukocyte peptidase inhibitor

increases expression

Didanosine results in increased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

isoquinoline-1,5-diol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2, apoptosis regulator

multiple interactions

[1,5-dihydroxyisoquinoline co-treated with Tretinoin] results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

endothelin 1

decreases expression

1,5-dihydroxyisoquinoline results in decreased expression of EDN1 mRNA; 1,5-dihydroxyisoquinoline results in decreased expression of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type A

decreases expression

1,5-dihydroxyisoquinoline results in decreased expression of EDNRA mRNA

NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049

G

endothelin receptor type B

decreases expression

1,5-dihydroxyisoquinoline results in decreased expression of EDNRB mRNA

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

high mobility group box 1

multiple interactions

1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased acetylation of HMGB1 protein]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of HMGB1 protein]

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

poly (ADP-ribose) polymerase 1

multiple interactions
decreases activity
decreases expression

1,5-dihydroxyisoquinoline inhibits the reaction [Vancomycin results in increased expression of PARP1 protein]
1,5-dihydroxyisoquinoline results in decreased activity of PARP1 protein
1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]]
1,5-dihydroxyisoquinoline results in decreased expression of PARP1 protein

PMID:12824290 PMID:19833176 PMID:25517228

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

sirtuin 1

multiple interactions

1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

N-methylnicotinamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of N-methylnicotinamide
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of N-methylnicotinamide]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

solute carrier organic anion transporter family, member 1a4

affects abundance

SLCO1A4 protein affects the abundance of N-methylnicotinamide

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

N-ribosylnicotinamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ERCC excision repair 6, chromatin remodeling factor

multiple interactions

nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]; nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD]

NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

multiple interactions
increases oxidation

[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of 2,6-Dichloroindophenol; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q1; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]
NQO2 protein results in increased oxidation of nicotinamide-beta-riboside; NQO2 protein results in increased oxidation of nicotinamide-beta-riboside metabolite

PMID:20399199 PMID:29281794

NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320

nicorandil

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 9

increases activity

Nicorandil results in increased activity of ABCC9 protein

NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356

G

angiotensinogen

multiple interactions

Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

albumin

multiple interactions

Nicorandil inhibits the reaction [Folic Acid results in decreased expression of ALB protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

BCL2 associated X, apoptosis regulator

multiple interactions

Nicorandil inhibits the reaction [Doxorubicin results in increased expression of BAX protein]
Nicorandil inhibits the reaction [Folic Acid results in increased expression of BAX protein]

PMID:31376360 PMID:33404076

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions

Nicorandil inhibits the reaction [Folic Acid results in increased expression of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cathepsin D

multiple interactions

[Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of CTSD protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of CTSD protein]

PMID:11829124 PMID:14499179

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

galanin and GMAP prepropeptide

multiple interactions

[Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GAL protein]

PMID:11829124 PMID:14499179

NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959

G

glucuronidase, beta

multiple interactions

[Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GUSB protein]

PMID:11829124 PMID:14499179

NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905

G

hepatitis A virus cellular receptor 1

multiple interactions

Nicorandil inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein]

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

heme oxygenase 1

decreases expression

Nicorandil results in decreased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

interleukin 1 beta

multiple interactions

Nicorandil inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Nicorandil inhibits the reaction [Folic Acid results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

myeloperoxidase

multiple interactions

Nicorandil inhibits the reaction [Doxorubicin results in increased expression of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

NFE2 like bZIP transcription factor 2

multiple interactions

Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

Nicorandil inhibits the reaction [Doxorubicin results in increased expression of NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nitric oxide synthase 2

multiple interactions

Nicorandil inhibits the reaction [Folic Acid results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions

Nicorandil inhibits the reaction [Folic Acid results in decreased expression of NOS3 protein]

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

superoxide dismutase 2

increases expression

Nicorandil results in increased expression of SOD2 protein

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

toll-like receptor 4

multiple interactions

Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TLR4 protein]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TNF protein]
Nicorandil inhibits the reaction [Folic Acid results in increased expression of TNF protein]

PMID:31376360 PMID:33404076

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

xanthine dehydrogenase

multiple interactions
decreases expression

Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein]
Nicorandil results in decreased expression of XDH protein

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

nicotinamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions

nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Abca1 protein in kidney]

RGD

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

acetyl-CoA carboxylase alpha

multiple interactions
decreases phosphorylation

Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein]
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]
Niacinamide results in decreased phosphorylation of ACACA protein

PMID:18482975 PMID:19071085 PMID:21212096

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

angiotensin I converting enzyme

multiple interactions

2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA]

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

multiple interactions

2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA]; [Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA]

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

adiponectin, C1Q and collagen domain containing

increases secretion
multiple interactions

Niacinamide results in increased secretion of ADIPOQ protein
[Alloxan co-treated with Niacinamide] affects the expression of ADIPOQ protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein]

PMID:17452443 PMID:21439372 PMID:26429928

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

argonaute RISC catalytic component 2

multiple interactions

Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein]

NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974

G

angiotensin II receptor, type 1a

multiple interactions

[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA]

PMID:18420994 PMID:37120126

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

AKT serine/threonine kinase 1

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

apoptotic peptidase activating factor 1

multiple interactions

[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of BAX protein]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX mRNA]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX protein]
[Berberine co-treated with Niacinamide] results in increased expression of BAX protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]
Niacinamide results in increased expression of BAX mRNA; Niacinamide results in increased expression of BAX protein

PMID:16168987 PMID:16998810 PMID:22164206 PMID:25478867 PMID:26712469

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

multiple interactions
increases expression

[Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA
Niacinamide results in increased expression of BBC3 mRNA

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

multiple interactions

[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]
[Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]

PMID:25472572 PMID:25478867 PMID:26712469

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 11

multiple interactions
increases expression

[Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein]
Niacinamide results in increased expression of BCL2L11 mRNA

PMID:25472572 PMID:26712469

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

BMI1 proto-oncogene, polycomb ring finger

multiple interactions

Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein]

NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690

G

caspase 3

multiple interactions
increases cleavage

Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased activity of CASP3 protein]
Niacinamide results in increased cleavage of CASP3 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; resveratrol inhibits the reaction [Niacinamide results in increased cleavage of CASP3 protein]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Niacinamide promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]

PMID:16505238 PMID:22164206 PMID:24040102 PMID:24962570 PMID:25478867 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]

PMID:16505238 PMID:25478867 PMID:26712469

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein]; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Saponins inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]

PMID:20307516 PMID:21382363 PMID:21439372 PMID:21630391 PMID:22056647 More...

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

decreases expression

Niacinamide results in decreased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

increases expression

Niacinamide results in increased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

CD36 molecule

decreases expression

nicotinamide decreases expression of Cd36 protein in kidney

RGD

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

CD38 molecule

multiple interactions

CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]

NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986

G

CD40 molecule

multiple interactions

Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA]

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression
decreases expression

Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein]
Niacinamide results in increased expression of CDKN1A protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]
Niacinamide results in decreased expression of CDKN1A protein

PMID:12782109 PMID:22561310 PMID:25478867

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression
multiple interactions

Niacinamide results in increased expression of CDKN1B protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2A

multiple interactions

Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter]

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

component of inhibitor of nuclear factor kappa B kinase complex

increases activity
multiple interactions

Niacinamide results in increased activity of CHUK protein
resveratrol inhibits the reaction [Niacinamide results in increased activity of CHUK protein]

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

collagen type I alpha 1 chain

decreases expression
multiple interactions

Niacinamide results in decreased expression of COL1A1 mRNA
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]

PMID:16813520 PMID:25707573

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

multiple interactions

Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]]

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

carnitine palmitoyltransferase 1A

decreases expression

Nicotinamide decreases expression of Cpt1a protein in kidney of 5/6 nephrectomized rats

RGD

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cytochrome b-245 alpha chain

multiple interactions
increases expression

Clofibrate inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]; GW 6471 inhibits the reaction [Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]]; Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome b-245 beta chain

multiple interactions

2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

Niacinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA]

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

defensin beta 5

multiple interactions

[Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA

NCBI chr16:70,612,985...70,615,389
Ensembl chr16:70,613,146...70,615,467

G

dicer 1 ribonuclease III

multiple interactions

Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein]

NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965

G

discs large MAGUK scaffold protein 1

multiple interactions

[Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; Niacinamide inhibits the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA]

NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689

G

DNA methyltransferase 1

multiple interactions

Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein]

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

eukaryotic translation initiation factor 4E binding protein 1

increases phosphorylation
multiple interactions

Niacinamide results in increased phosphorylation of EIF4EBP1 protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Niacinamide inhibits the reaction [Resveratrol results in decreased phosphorylation of EIF4EBP1 protein]

PMID:19928762 PMID:20169165

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

ERCC excision repair 6, chromatin remodeling factor

increases abundance
multiple interactions

ERCC6 gene mutant form results in increased abundance of Niacinamide
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased abundance of Niacinamide]

NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587

G

coagulation factor III, tissue factor

decreases expression

Niacinamide results in decreased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fatty acid binding protein 1

multiple interactions

nicotinamide inhibits the reaction [5/6 nephrectomy decreases the expression of Fabp1 protein in kidney]

RGD

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

Fas ligand

multiple interactions

CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of FOS protein]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box O1

multiple interactions

Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC1 mRNA]; Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA]
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Niacinamide results in increased expression of and results in increased acetylation of FOXO1 protein
Niacinamide inhibits the reaction [Dexamethasone results in decreased acetylation of FOXO1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]

PMID:16917544 PMID:20181797 PMID:26712469

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

forkhead box O3

multiple interactions

[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of and results in increased expression of FOXO3 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of FOXO3 protein]; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of FOXO3 protein]; Niacinamide results in increased expression of and results in increased acetylation of FOXO3 protein

PMID:23022493 PMID:25472572 PMID:26712469

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

ferritin heavy chain 1

increases expression

Niacinamide results in increased expression of FTH1 mRNA; Niacinamide results in increased expression of FTH1 protein

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC1 mRNA]

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glucose-6-phosphate dehydrogenase

multiple interactions

[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein]

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glucagon

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA; Sitagliptin Phosphate inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA]

NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

galactosidase, beta 1

multiple interactions
increases expression

Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Niacinamide results in increased expression of GLB1 protein

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

glyoxalase 1

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]

NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649

G

glutamic--pyruvic transaminase

multiple interactions

[Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione-disulfide reductase

multiple interactions

[Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in decreased expression of GSR protein]; [Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]

PMID:20307516 PMID:21439372 PMID:32894639

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase, mu 5

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

glutathione S-transferase pi 1

multiple interactions

[Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of GSTP1 protein]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glycogen synthase 2

multiple interactions

[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein]

NCBI chr 4:175,365,054...175,406,228
Ensembl chr 4:175,365,054...175,406,228

G

hemoglobin alpha, adult chain 2

multiple interactions

[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein]

NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392

G

histone deacetylase 1

multiple interactions

Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein]

NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
decreases expression

[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]
Nicotinamide decreases expression of Hmgcr protein in kidney of 5/6 nephrectomized rats

CTD
RGD

PMID:20696151 PMID:21212096 PMID:19878707

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

heme oxygenase 1

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

intercellular adhesion molecule 1

multiple interactions

Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interferon gamma

multiple interactions

[Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor binding protein 1

multiple interactions

Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA]

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

interleukin 10

multiple interactions

2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein]; [Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 18

multiple interactions

[Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL18 mRNA

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions
decreases expression
increases expression

[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein; [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL1B mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]
Niacinamide results in decreased expression of IL1B mRNA
Niacinamide results in increased expression of IL1B mRNA

PMID:20307516 PMID:21439372 PMID:22385246 PMID:28322830 PMID:29594315

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

multiple interactions

[Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 6

decreases expression
multiple interactions

Niacinamide results in decreased expression of IL6 protein
[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]

PMID:12727023 PMID:20307516 PMID:21439372

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

[Niacinamide co-treated with Streptozocin] results in decreased expression of INS1 protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein; [Streptozocin co-treated with Niacinamide] results in decreased secretion of INS1 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased expression of INS1 protein]; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS1 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased secretion of INS1 protein]

PMID:16366736 PMID:19647726 PMID:21382363 PMID:21630391 PMID:25999625 More...

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

insulin receptor

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein]

NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883

G

insulin receptor substrate 2

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein]

NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of JUN protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

Kelch-like ECH-associated protein 1

multiple interactions

[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]
2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA]; [Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA]

PMID:21439372 PMID:37120126

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

KLF transcription factor 4

multiple interactions

[Streptozocin co-treated with Niacinamide] promotes the reaction [Dronabinol results in increased expression of KLF4 mRNA]

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

lecithin cholesterol acyltransferase

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]

NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231

G

luteinizing hormone subunit beta

multiple interactions

Niacinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

lipoprotein lipase

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

MAF bZIP transcription factor A

multiple interactions

Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]

NCBI chr 7:107,432,292...107,435,084
Ensembl chr 7:107,433,605...107,434,690

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen-activated protein kinase 8

multiple interactions

Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

MDM2 proto-oncogene

increases expression

Niacinamide results in increased expression of MDM2 mRNA

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

microRNA 200a

multiple interactions

2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A]; [Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A]

NCBI chr 5:166,648,494...166,648,582

G

microRNA 3545

multiple interactions

Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter]

NCBI chr 6:131,199,542...131,199,656
Ensembl chr 6:131,199,542...131,199,656

G

MLX interacting protein-like

multiple interactions

nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Mlxipl protein in kidney]

RGD

NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112

G

matrix metallopeptidase 9

increases expression
multiple interactions

Niacinamide results in increased expression of MMP9 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of MMP9 protein]

PMID:24145604 PMID:24962570

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

methionine sulfoxide reductase A

multiple interactions

Niacinamide inhibits the reaction [resveratrol results in increased expression of MSRA protein]

NCBI chr15:38,363,459...38,677,406
Ensembl chr15:38,351,445...38,676,585

G

mitochondrially encoded cytochrome c oxidase I

increases expression

Niacinamide results in increased expression of COX1 mRNA; Niacinamide results in increased expression of COX1 protein

NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867

G

mechanistic target of rapamycin kinase

increases phosphorylation
multiple interactions

Niacinamide results in increased phosphorylation of MTOR protein
Niacinamide inhibits the reaction [resveratrol results in decreased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in increased expression of and results in increased localization of MYC protein]

PMID:22028816 PMID:24792773

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

nucleic acid binding protein 2

decreases ubiquitination
increases acetylation
multiple interactions

Niacinamide results in decreased ubiquitination of NABP2 protein
Niacinamide results in increased acetylation of NABP2 protein
Niacinamide promotes the reaction [trichostatin A results in decreased ubiquitination of NABP2 protein]; Niacinamide promotes the reaction [trichostatin A results in increased acetylation of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in decreased ubiquitination of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in increased acetylation of NABP2 protein]

NCBI chr 7:830,949...836,551
Ensembl chr 7:830,949...838,027

G

nicotinamide phosphoribosyltransferase

decreases expression
multiple interactions

Niacinamide results in decreased expression of NAMPT protein
Niacinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA]
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein

PMID:26712469 PMID:32298659

NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100

G

nuclear receptor co-repressor 1

decreases expression
multiple interactions

Niacinamide results in decreased expression of NCOR1 protein
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]

NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032

G

NADH:ubiquinone oxidoreductase subunit A1

multiple interactions

Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA1 mRNA]

NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633

G

NADH:ubiquinone oxidoreductase subunit A13

multiple interactions

Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 mRNA]; Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 protein]

NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726

G

NADH:ubiquinone oxidoreductase subunit A2

multiple interactions

Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA2 mRNA]

NCBI chr18:28,355,774...28,357,863
Ensembl chr18:28,355,774...28,358,076

G

NFE2 like bZIP transcription factor 2

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]
2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein]

PMID:21439372 PMID:37120126

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

[Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of NFKB1 mRNA]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nitric oxide synthase 2

multiple interactions

Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 mRNA]; Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NADPH oxidase 4

multiple interactions
increases expression

GW 6471 inhibits the reaction [resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA

NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297

G

oxoglutarate dehydrogenase

multiple interactions

Niacinamide inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of OGDH protein]

NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases expression
increases cleavage
decreases activity

Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of PARP1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased cleavage of PARP1 protein]
Niacinamide results in increased expression of PARP1 mRNA; Niacinamide results in increased expression of PARP1 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Niacinamide inhibits the reaction [sodium arsenite results in decreased expression of PARP1 protein]
Niacinamide results in increased cleavage of PARP1 protein
Niacinamide results in decreased activity of PARP1 protein

PMID:16168987 PMID:19288225 PMID:22164206 PMID:26712469 PMID:29143419 More...

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

pyruvate dehydrogenase kinase 4

multiple interactions

Niacinamide inhibits the reaction [Dexamethasone results in increased expression of PDK4 protein]

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

pyruvate dehydrogenase phosphatase catalytic subunit 1

multiple interactions

Niacinamide inhibits the reaction [Dexamethasone results in increased phosphorylation of PDP1 protein]

NCBI chr 5:25,446,843...25,455,107
Ensembl chr 5:25,446,272...25,455,217

G

paired-like homeodomain 2

increases expression

Niacinamide results in increased expression of PITX2 mRNA; Niacinamide results in increased expression of PITX2 protein

NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293

G

peripheral myelin protein 22

multiple interactions

Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of and results in decreased localization of PMP22 protein]

NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PPARG protein]
[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein]

PMID:22539994 PMID:37566541

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

increases acetylation
multiple interactions

Niacinamide results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]

PMID:19071085 PMID:23422569 PMID:23891692

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein kinase AMP-activated catalytic subunit alpha 1

multiple interactions

Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA1 protein]

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

protein kinase AMP-activated catalytic subunit alpha 2

multiple interactions

Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA2 protein]

NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

Niacinamide results in increased expression of PTGS2 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PTGS2 protein]

PMID:24145604 PMID:24962570

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

glycogen phosphorylase L

multiple interactions

[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein]

NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Metformin inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Salicylic Acid inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]
Niacinamide results in increased acetylation of and results in increased phosphorylation of RELA protein; resveratrol inhibits the reaction [Niacinamide results in increased phosphorylation of and results in increased acetylation of RELA protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein]; [Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein]; Niacinamide inhibits the reaction [Resveratrol results in decreased expression of RELA protein modified form]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]

PMID:20307516 PMID:21439372 PMID:22717288 PMID:23406761 PMID:23735732 More...

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ribosomal protein S6

multiple interactions

[Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

RUNX family transcription factor 2

decreases expression
multiple interactions
increases expression

Niacinamide results in decreased expression of RUNX2 mRNA; Niacinamide results in decreased expression of RUNX2 protein
resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein]
Niacinamide results in increased expression of RUNX2 mRNA

PMID:16813520 PMID:22539994

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

SR-related CTD-associated factor 1

increases expression

nicotinamide increases expression of Scaf1 protein in kidney

RGD

NCBI chr 1:95,485,448...95,499,389
Ensembl chr 1:95,485,448...95,496,029

G

SREBF chaperone

increases expression

nicotinamide increases expression of Scap protein in kidney of 5/6 nephrectomized rat

RGD

NCBI chr 8:110,306,026...110,360,677
Ensembl chr 8:110,306,031...110,360,666

G

scavenger receptor class B, member 1

decreases expression

nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Scarb1 protein in kidney]

RGD

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

SHC adaptor protein 1

multiple interactions
increases expression

Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein]
Niacinamide results in increased expression of SHC1 mRNA; Niacinamide results in increased expression of SHC1 protein

PMID:21778425 PMID:24557422

NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536

G

sirtuin 1

multiple interactions
decreases expression
decreases activity

[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol; Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA]
Niacinamide results in decreased expression of SIRT1 protein
[Niacinamide co-treated with Resveratrol] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Fructose; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Metformin; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Resveratrol; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Salicylic Acid; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA; [Resveratrol co-treated with Niacinamide] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of and results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]; Niacinamide inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 mRNA]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]
Niacinamide results in decreased expression of SIRT1 mRNA; Niacinamide results in decreased expression of SIRT1 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of CXCL8 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased susceptibility to Hydrogen Peroxide; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]

PMID:16366736 PMID:17103016 PMID:18420994 PMID:18482975 PMID:18681908 More...

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

sirtuin 2

decreases activity
multiple interactions

Niacinamide results in decreased activity of SIRT2 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein

PMID:17341628 PMID:26712469

NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975

G

sirtuin 3

multiple interactions

[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein

NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808

G

solute carrier family 2 member 4

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein]; Niacinamide inhibits the reaction [Letrozole results in decreased expression of SLC2A4 mRNA]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein]

PMID:32298659 PMID:37566541

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier organic anion transporter family, member 1a4

affects abundance

SLCO1A4 protein affects the abundance of Niacinamide

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

synaptosome associated protein 23

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA]

NCBI chr 3:107,514,088...107,546,177
Ensembl chr 3:107,514,131...107,544,320

G

superoxide dismutase 1

multiple interactions

[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein; Dronabinol promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein]; [Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein]

PMID:31081965 PMID:37120126

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions

Niacinamide inhibits the reaction [resveratrol results in increased expression of SOD2 mRNA]
Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SOD2 protein]

PMID:23891692 PMID:25472572

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

SRY-box transcription factor 9

decreases expression
multiple interactions

Niacinamide results in decreased expression of SOX9 protein
4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]; resveratrol inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

sequestosome 1

multiple interactions

Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

multiple interactions

Niacinamide inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

syntaxin 4

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA]

NCBI chr 1:182,451,108...182,459,701
Ensembl chr 1:182,451,117...182,459,979

G

transforming growth factor, beta 1

multiple interactions

2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta 2

multiple interactions

Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]]

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

tumor necrosis factor

multiple interactions
increases expression

[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]
Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]; Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA]
Niacinamide results in increased expression of TNF mRNA

PMID:20307516 PMID:21439372 PMID:22385246 PMID:22717288 PMID:24145604 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 11B

decreases expression

Niacinamide results in decreased expression of TNFRSF11B mRNA

NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538

G

TNF superfamily member 11

decreases expression

Niacinamide results in decreased expression of TNFSF11 mRNA

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

tumor protein p53

multiple interactions
decreases expression

[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]; Niacinamide results in increased phosphorylation of and results in increased acetylation of TP53 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]
Niacinamide results in decreased expression of TP53 protein

PMID:12782109 PMID:18482975 PMID:18681908 PMID:25478867 PMID:26712469

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tyrosinase

increases expression

Niacinamide results in increased expression of TYR mRNA; Niacinamide results in increased expression of TYR protein

NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207

G

uncoupling protein 2

multiple interactions

Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA]

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

vesicle-associated membrane protein 2

multiple interactions

[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA]

NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809

niraparib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

H2A.X variant histone

increases expression
multiple interactions

niraparib results in increased expression of H2AX protein
diphenyleneiodonium inhibits the reaction [niraparib results in increased expression of H2AX protein]

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

poly (ADP-ribose) polymerase 1

multiple interactions

niraparib binds to and results in decreased activity of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

poly (ADP-ribose) polymerase 2

multiple interactions

niraparib binds to and results in decreased activity of PARP2 protein

NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338

NU 1025

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ERCC excision repair 6, chromatin remodeling factor

multiple interactions
affects response to substance

NU 1025 inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]
ERCC6 gene mutant form affects the susceptibility to NU 1025

NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587

olaparib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

multiple interactions

[Dietary Fats co-treated with olaparib] results in decreased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acetyl-CoA carboxylase beta

multiple interactions

[Dietary Fats co-treated with olaparib] results in decreased expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

acyl-CoA oxidase 1

multiple interactions

[Dietary Fats co-treated with olaparib] results in decreased expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

actin alpha 2, smooth muscle

multiple interactions

olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACTA2 mRNA]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adhesion G protein-coupled receptor E1

multiple interactions

olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ADGRE1 mRNA]

NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions

olaparib inhibits the reaction [Methylmercury Compounds results in increased expression of AIFM1 protein]

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

AKT serine/threonine kinase 1

multiple interactions

olaparib promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; olaparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

Brca1 associated protein 1

increases response to substance

BAP1 gene mutant form results in increased susceptibility to olaparib

NCBI chr16:6,446,709...6,455,535
Ensembl chr16:6,446,709...6,455,535

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

INCB054329 promotes the reaction [olaparib results in increased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

olaparib results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

baculoviral IAP repeat-containing 5

decreases expression

olaparib results in decreased expression of BIRC5 protein

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

BRCA1, DNA repair associated

affects response to substance
multiple interactions

BRCA1 affects the susceptibility to olaparib
[BRD4 protein affects the susceptibility to olaparib] which affects the expression of BRCA1 protein; [olaparib co-treated with INCB054329] results in decreased expression of BRCA1 protein; olaparib promotes the reaction [INCB054329 results in decreased expression of BRCA1 protein]

PMID:21633166 PMID:29567272

NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304

G

BRCA2, DNA repair associated

affects response to substance

BRCA2 affects the susceptibility to olaparib

NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567

G

bromodomain containing 4

multiple interactions
affects response to substance

[BRD4 protein affects the susceptibility to olaparib] which affects the cleavage of PARP1 protein; [BRD4 protein affects the susceptibility to olaparib] which affects the expression of BRCA1 protein; [BRD4 protein affects the susceptibility to olaparib] which affects the expression of H2AX protein

NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539

G

caspase 3

multiple interactions

[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP3 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP3 protein]; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; olaparib inhibits the reaction [Methylmercury Compounds results in increased cleavage of CASP3 protein]

PMID:25531448 PMID:26544897 PMID:35396826

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP8 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP8 protein]; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]

PMID:25531448 PMID:26544897

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; olaparib inhibits the reaction [Methylmercury Compounds results in increased expression of CASP9 protein]

PMID:25531448 PMID:35396826

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine ligand 2

multiple interactions

olaparib inhibits the reaction [Ethanol results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cellular communication network factor 2

multiple interactions

olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCN2 mRNA]

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin E1

multiple interactions

[olaparib co-treated with INCB054329] results in decreased expression of CCNE1 protein; olaparib promotes the reaction [INCB054329 results in decreased expression of CCNE1 protein]

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

C-C motif chemokine receptor 2

multiple interactions

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

olaparib results in increased expression of CDKN1A protein
INCB054329 promotes the reaction [olaparib results in increased expression of CDKN1A protein]; olaparib promotes the reaction [INCB054329 results in increased expression of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

checkpoint kinase 1

increases phosphorylation

olaparib results in increased phosphorylation of CHEK1 protein

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

collagen type I alpha 1 chain

multiple interactions

olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

CCCTC-binding factor

decreases binding

olaparib decreases binding of CTCF to Cp promoter region in human lymphoblastoid cell lines

RGD

NCBI chr19:33,521,726...33,571,124
Ensembl chr19:33,529,319...33,571,123

G

C-X-C motif chemokine ligand 2

multiple interactions

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of CXCL2 mRNA; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CXCL2 mRNA]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

cytochrome c, somatic

multiple interactions

olaparib inhibits the reaction [Methylmercury Compounds results in increased expression of CYCS protein]

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

DDIT3 protein affects the reaction [[TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein]
olaparib results in increased expression of DDIT3 protein

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

fatty acid synthase

multiple interactions

[Dietary Fats co-treated with olaparib] results in decreased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fumarate hydratase

increases response to substance

FH mutant form results in increased susceptibility to olaparib

NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266

G

glutamic--pyruvic transaminase

multiple interactions

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of GPT protein; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

H2A.X variant histone

multiple interactions
increases phosphorylation
increases expression

(+)-JQ1 compound promotes the reaction [olaparib results in increased expression of H2AX protein]; [BRD4 protein affects the susceptibility to olaparib] which affects the expression of H2AX protein; [Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]; INCB054329 promotes the reaction [olaparib results in increased expression of H2AX protein]; olaparib promotes the reaction [(+)-JQ1 compound results in increased expression of H2AX protein]; olaparib promotes the reaction [INCB054329 results in increased expression of H2AX protein]; TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]]
olaparib results in increased phosphorylation of H2AX protein

PMID:25531448 PMID:26544897 PMID:29567272

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

high mobility group box 1

multiple interactions

olaparib inhibits the reaction [Ethanol results in increased expression of HMGB1 protein]

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

intercellular adhesion molecule 1

multiple interactions

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of ICAM1 mRNA

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 1 beta

multiple interactions

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

olaparib inhibits the reaction [Ethanol results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]
bafilomycin A1 inhibits the reaction [olaparib inhibits the reaction [Hydrogen Peroxide results in increased lipidation of MAP1LC3B protein]]; olaparib inhibits the reaction [Hydrogen Peroxide results in increased lipidation of MAP1LC3B protein]

PMID:34826546 PMID:36639873

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

marker of proliferation Ki-67

decreases expression
multiple interactions

olaparib results in decreased expression of MKI67 protein
INCB054329 promotes the reaction [olaparib results in decreased expression of MKI67 protein]; olaparib promotes the reaction [INCB054329 results in decreased expression of MKI67 protein]

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

mutL homolog 1

multiple interactions

olaparib inhibits the reaction [MLH1 protein results in decreased susceptibility to Floxuridine]

NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617

G

myeloperoxidase

multiple interactions

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of MPO protein

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mutS homolog 2

multiple interactions

olaparib inhibits the reaction [MSH2 protein results in decreased susceptibility to Floxuridine]

NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938

G

mutS homolog 3

decreases response to substance

MSH3 protein results in decreased susceptibility to olaparib

NCBI chr 2:23,444,326...23,585,777

G

poly (ADP-ribose) polymerase 1

multiple interactions
decreases activity
decreases binding
increases cleavage

olaparib inhibits the reaction [Hydrogen Peroxide results in increased activity of PARP1 protein]
olaparib results in decreased activity of PARP1 protein
olaparib decreases binding of PARP1 to Cp promoter region in human lymphoblastoid cell lines
(+)-JQ1 compound promotes the reaction [olaparib results in increased cleavage of PARP1 protein]; [BRD4 protein affects the susceptibility to olaparib] which affects the cleavage of PARP1 protein; INCB054329 promotes the reaction [olaparib results in increased cleavage of PARP1 protein]; olaparib inhibits the reaction [Methylmercury Compounds results in increased cleavage of PARP1 protein]; olaparib promotes the reaction [INCB054329 results in increased cleavage of PARP1 protein]

CTD
RGD

PMID:24814482 PMID:28001384 PMID:29567272 PMID:35396826 PMID:29976663

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

poly (ADP-ribose) polymerase 2

multiple interactions

olaparib binds to and results in decreased activity of PARP2 protein

NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338

G

proliferating cell nuclear antigen

multiple interactions
decreases expression

INCB054329 promotes the reaction [olaparib results in decreased expression of PCNA protein]

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

phospholipase A2 group IIA

multiple interactions

olaparib inhibits the reaction [Ethanol results in increased expression of PLA2G2A protein]

NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014

G

phospholipase A2 group IVA

multiple interactions

olaparib inhibits the reaction [Ethanol results in increased expression of PLA2G4A protein]

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

peroxisome proliferator activated receptor alpha

multiple interactions

[Dietary Fats co-treated with olaparib] results in decreased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

RAD51 recombinase

multiple interactions

[olaparib co-treated with INCB054329] results in decreased expression of RAD51 protein

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

succinate dehydrogenase complex iron sulfur subunit B

increases response to substance

SDHB mutant form results in increased susceptibility to olaparib

NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293

G

sirtuin 1

increases expression
multiple interactions

olaparib results in increased expression of SIRT1 protein
olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

sequestosome 1

multiple interactions

olaparib inhibits the reaction [Hydrogen Peroxide results in decreased expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

multiple interactions

[Dietary Fats co-treated with olaparib] results in decreased expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

transforming growth factor, beta 1

multiple interactions

olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

[Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of TNF mRNA; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF mRNA]; olaparib inhibits the reaction [Ethanol results in increased expression of TNF protein]

PMID:27984176 PMID:29317476

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 10

multiple interactions

[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [[TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein]

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

tumor protein p53

multiple interactions
increases phosphorylation

[Fluorouracil co-treated with olaparib] results in increased expression of TP53 protein; TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]]
olaparib results in increased phosphorylation of TP53 protein

PMID:25531448 PMID:26544897

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

X-ray repair cross complementing 1

multiple interactions

olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]

NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701

phenanthridone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions

phenanthridone inhibits the reaction [Methylnitronitrosoguanidine results in increased localization of AIFM1 protein]

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

caspase 7

multiple interactions

[eprenetapopt co-treated with phenanthridone] results in increased cleavage of CASP7 protein

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 9

multiple interactions

[eprenetapopt co-treated with phenanthridone] results in increased cleavage of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine ligand 3

multiple interactions

phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

CD83 molecule

decreases expression

phenanthridone results in decreased expression of CD83 mRNA; phenanthridone results in decreased expression of CD83 protein

NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083

G

CD86 molecule

decreases expression

phenanthridone results in decreased expression of CD86 mRNA; phenanthridone results in decreased expression of CD86 protein

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

C-X-C motif chemokine ligand 2

multiple interactions

phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CXCL2 protein]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

H2A.X variant histone

increases expression
multiple interactions

phenanthridone results in increased expression of H2AX protein modified form
Acetylcysteine inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form]; TXNRD1 protein inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form]

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

interferon gamma

multiple interactions
decreases expression

phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA]
phenanthridone results in decreased expression of IFNG mRNA

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions

phenanthridone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12B

multiple interactions

phenanthridone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 1 beta

decreases expression

phenanthridone results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

decreases expression
multiple interactions

phenanthridone results in decreased expression of IL2 mRNA
phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

kinesin family member 18A

increases metabolic processing

phenanthridone results in increased metabolism of KIF18A protein

NCBI chr 3:95,764,388...95,824,756
Ensembl chr 3:95,764,388...95,824,582

G

kinesin family member C1

increases metabolic processing

phenanthridone results in increased metabolism of KIFC1 protein

NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105

G

nitric oxide synthase 2

decreases expression

phenanthridone results in decreased expression of NOS2 mRNA

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

poly (ADP-ribose) polymerase 1

decreases activity
multiple interactions

phenanthridone results in decreased activity of PARP1 protein
[eprenetapopt co-treated with phenanthridone] results in increased cleavage of PARP1 protein

PMID:12411406 PMID:29416738

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

prostaglandin-endoperoxide synthase 2

decreases expression

phenanthridone results in decreased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

tumor necrosis factor

multiple interactions
decreases expression

phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA]
phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of TNF protein]
phenanthridone results in decreased expression of TNF mRNA

PMID:12006805 PMID:12411406

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

thioredoxin reductase 1

multiple interactions
decreases expression

TXNRD1 protein inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form]
phenanthridone results in decreased expression of TXNRD1 mRNA; phenanthridone results in decreased expression of TXNRD1 protein

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

PJ34

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

integrin subunit alpha M

decreases expression

PJ34 decreases expression of Itgam mRNA and protein in ischemic brain

RGD

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

rucaparib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Bcl2-like 1

affects response to substance

BCL2L1 protein affects the susceptibility to rucaparib

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

BRCA1, DNA repair associated

affects response to substance

BRCA1 protein affects the susceptibility to rucaparib

NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304

G

bromodomain containing 4

affects response to substance

BRD4 protein affects the susceptibility to rucaparib

NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539

G

caspase 3

increases expression
multiple interactions

rucaparib results in increased expression of CASP3 protein
[Irinotecan co-treated with rucaparib] results in increased expression of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

C-C motif chemokine ligand 2

multiple interactions

rucaparib inhibits the reaction [Ethanol results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin D1

multiple interactions

[rucaparib co-treated with Dasatinib] results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin-dependent kinase 9

affects response to substance

CDK9 protein affects the susceptibility to rucaparib

NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410

G

H2A.X variant histone

multiple interactions
affects expression

[Irinotecan co-treated with rucaparib] results in increased expression of H2AX protein; [rucaparib co-treated with CPI-0610] results in increased expression of H2AX protein; [rucaparib co-treated with Dasatinib co-treated with CPI-0610] results in increased expression of H2AX protein; [rucaparib co-treated with Dasatinib] results in increased expression of H2AX protein
rucaparib affects the expression of H2AX protein

PMID:30612311 PMID:32927276

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

interleukin 6

multiple interactions

rucaparib inhibits the reaction [Ethanol results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

marker of proliferation Ki-67

multiple interactions

[Irinotecan co-treated with rucaparib] results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

poly (ADP-ribose) polymerase 1

multiple interactions
decreases expression

[rucaparib co-treated with Dasatinib co-treated with CPI-0610] results in increased cleavage of PARP1 protein; rucaparib binds to and results in decreased activity of PARP1 protein; rucaparib inhibits the reaction [Irinotecan results in increased expression of PARP1 protein]; rucaparib promotes the reaction [navitoclax results in increased cleavage of PARP1 protein]
rucaparib results in decreased expression of PARP1 protein

PMID:28001384 PMID:30612311 PMID:32927276

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

poly (ADP-ribose) polymerase 2

decreases activity

rucaparib results in decreased activity of PARP2 protein

NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338

G

ribosomal protein S6 kinase B1

multiple interactions

[Irinotecan co-treated with rucaparib] results in decreased expression of RPS6KB1 protein

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

SRC proto-oncogene, non-receptor tyrosine kinase

affects response to substance
multiple interactions
increases phosphorylation

SRC protein affects the susceptibility to rucaparib
[rucaparib co-treated with Dasatinib] results in decreased phosphorylation of SRC protein
rucaparib results in increased phosphorylation of SRC protein

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

tumor necrosis factor

multiple interactions

rucaparib inhibits the reaction [Ethanol results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tankyrase 2

affects binding

rucaparib binds to TNKS2 protein

NCBI chr 1:234,567,888...234,621,079
Ensembl chr 1:234,567,858...234,621,079

veliparib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases transport

ABCB1 protein results in increased transport of veliparib

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

AKT serine/threonine kinase 1

multiple interactions

veliparib promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; veliparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

ATM serine/threonine kinase

multiple interactions
increases activity

veliparib results in increased phosphorylation of and results in increased activity of ATM protein
veliparib results in increased activity of ATM protein

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

BCL2-antagonist/killer 1

multiple interactions

BAK1 protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib]

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

multiple interactions

BAX protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl2-like 1

multiple interactions

BCL2L1 protein results in decreased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

BRCA1, DNA repair associated

affects response to substance
decreases response to substance

BRCA1 affects the susceptibility to veliparib
BRCA1 protein results in decreased susceptibility to veliparib

PMID:21633166 PMID:21707865

NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304

G

BRCA2, DNA repair associated

affects response to substance

BRCA2 affects the susceptibility to veliparib

NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567

G

cyclin-dependent kinase 12

affects response to substance

CDK12 protein affects the susceptibility to veliparib

NCBI chr10:83,201,177...83,256,906
Ensembl chr10:83,201,211...83,280,888
Ensembl chr10:83,201,211...83,280,888

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases metabolic processing

CYP1A2 protein results in increased metabolism of veliparib

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases metabolic processing

CYP2C19 protein results in increased metabolism of veliparib

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases metabolic processing

CYP2D6 protein results in increased metabolism of veliparib

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases metabolic processing

CYP3A4 protein results in increased metabolism of veliparib

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

epidermal growth factor receptor

decreases response to substance
affects localization

EGFR protein results in decreased susceptibility to veliparib
veliparib affects the localization of EGFR protein

PMID:21719137 PMID:21912620

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

ERCC excision repair 1, endonuclease non-catalytic subunit

multiple interactions

ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

ERCC excision repair 4, endonuclease catalytic subunit

multiple interactions

ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]

NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369

G

ERCC excision repair 6, chromatin remodeling factor

multiple interactions

veliparib promotes the reaction [ERCC6 protein affects the susceptibility to potassium bromate]

NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587

G

H2A.X variant histone

multiple interactions
increases expression

[veliparib co-treated with Topotecan] results in increased expression of H2AX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]
[veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein modified form

PMID:17505006 PMID:21227924 PMID:21795476 PMID:21917757 PMID:27694308

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

interleukin 1 beta

multiple interactions

veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

N-methylpurine-DNA glycosylase

multiple interactions

MPG protein promotes the reaction [veliparib results in increased susceptibility to temozolomide]

NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520

G

MRE11 homolog, double strand break repair nuclease

decreases response to substance

MRE11 protein results in decreased susceptibility to veliparib

NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279

G

nitric oxide synthase 2

multiple interactions

veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

poly (ADP-ribose) polymerase 1

multiple interactions
decreases activity
increases expression

PARP1 protein affects the susceptibility to [Temozolomide co-treated with veliparib]; veliparib binds to and results in decreased activity of PARP1 protein; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form]
veliparib results in decreased activity of PARP1 protein
[veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of PARP1 protein; veliparib results in increased expression of PARP1 protein mutant form
[veliparib results in decreased activity of PARP1 protein] which results in increased susceptibility to Camptothecin

PMID:17505006 PMID:19143569 PMID:19823047 PMID:19825992 PMID:21300766 More...

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

poly (ADP-ribose) polymerase family, member 10

affects binding

veliparib binds to PARP10 protein

NCBI chr 7:107,949,031...107,958,377
Ensembl chr 7:107,949,043...107,958,304

G

poly (ADP-ribose) polymerase 2

affects binding
multiple interactions
decreases activity

PARP2 protein binds to veliparib
veliparib binds to and results in decreased activity of PARP2 protein
veliparib results in decreased activity of PARP2 protein

PMID:19143569 PMID:20092359 PMID:21917757 PMID:28001384

NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338

G

phosphatase and tensin homolog

decreases response to substance

PTEN protein results in decreased susceptibility to veliparib

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

replication protein A2

multiple interactions

veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form]

NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350

G

S100 calcium binding protein B

multiple interactions

veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA]; veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA]

NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743

G

tyrosyl-DNA phosphodiesterase 1

multiple interactions

TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]

NCBI chr 6:119,163,192...119,231,029
Ensembl chr 6:119,163,166...119,231,021

G

X-ray repair cross complementing 1

multiple interactions

veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]

NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19831
role	19807
biological role	19805
biochemical role	19515
enzyme inhibitor	18723
EC 2.* (transferase) inhibitor	14869
EC 2.4.* (glycosyltransferase) inhibitor	520
EC 2.4.2.* (pentosyltransferase) inhibitor	261
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor +	7
EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitor +	0
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor +	255
EC 2.4.2.4 (thymidine phosphorylase) inhibitor +	0
EC 2.4.2.8 (hypoxanthine phosphoribosyltransferase) inhibitor +	0

paths to the root